People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide.
People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.Video above: Drugmaker warns of copy-cat weight loss medsResearchers from Truveta, a health data analytics company, analyzed electronic health records for more than 18,000 adults, all of whom had overweight or obesity, who were taking these medications in the real world between May 2022 and September 2023.
Eli Lilly manufactures tirzepatide under the brand name Mounjaro for diabetes and Zepbound for chronic weight management, while Novo Nordisk manufacturers semaglutide as Ozempic for diabetes and Wegovy for weight management.The FDA approved higher doses of both tirzepatide and semaglutide to treat weight loss, but the new study only looked at the doses to treat type 2 diabetes.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsWith more people using drugs like Ozempic and Wegovy for weight loss, food companies are paying close attention and trying to adapt to changing eating habits.
Read more »
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsPeople taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.
Read more »
Ozempic, Mounjaro users turning to protein shakes to help beef up musclesOzempic and Mounjaro users are increasingly turning to protein drinks as a convenient way to supplement protein consumption and combat excess muscle loss.
Read more »
Study finds Mounjaro 'significantly more' effective than Ozempic for weight lossOverweight and obese adults using popular diabetes medications to suppress their appetites are 'significantly more likely' to shed pounds with Eli Lilly's Mounjaro than with Novo Nordisk's Ozempic, a new study has found, a result that could have major implications for one of the hottest new markets in the pharmaceutical field.
Read more »
Mounjaro bests Ozempic for weight loss in first head-to-head comparison of real-world useIn the first head-to-head comparison of two blockbuster drugs, patients taking Mounjaro lost more weight than those taking Ozempic.
Read more »
Ozempic vs. Mounjaro: New study reveals which is better to combat obesityBeyond Traditional Diet Pills: Groundbreaking New Weight Loss Drug Is More Effective Than Current Treatments
Read more »